N/A-testing NOT APPLICABLE to organism. CZOL-cefazolin, CTRX-ceftriaxone, CTAZ-ceftazidime, CFPM-cefepime, GEN-gentamicin, TOB-tobramycin, T/S-trimethoprim/sulfamethoxazole, CIP-ciprofloxacin, MER-meropenem, P/T-piperacillin-tazobactam
Values are % of strains testing susceptible to listed antibiotic. Unless indicated, results are for all inpatient/ED locations and culture sites.
Susceptibilities are based on data from 2019. Isolate numbers and 95% confidence intervals are provided to gauge precision of susceptibility estimate.
| Organism | Total Isolates |
CZOL %S (95% CI) |
CTRX %S (95% CI) |
CTAZ %S (95% CI) |
CFPM %S (95% CI) |
GEN %S (95% CI) |
TOB %S (95% CI) |
T/S %S (95% CI) |
CIP %S (95% CI) |
P/T %S (95% CI) |
MER %S (95% CI) |
|
Citrobacter freundii |
9* |
N/A |
88 (52,99) |
88 (52,99) |
100 (66,100) |
88 (52,99) |
88 (52,99) |
66 (30,93) |
100 (66,100) |
88 (52,99) |
100 (66,100) |
|
Enterobacter cloacae |
37 |
N/A |
N/A |
N/A |
86 (97)# (67,94) |
100 (91,100) |
97 (86,100) |
86 (71,95) |
91 (78,98) |
75 (59,88) |
97 (86,100) |
|
Escherichia coli |
108 |
55** (46,65) |
87 (79,93) |
87 (79,93) |
88 (93)# (81,94) |
87 (79,93) |
88 (81,94) |
64 (55,74) |
76 (68,84) |
97 (92,99) |
100 (97,100) |
|
Klebsiella oxytoca |
15* |
6** (0,32) |
93 (68,99) |
100 (78,100) |
100 (78,100) |
100 (78,100) |
100 (78,100) |
86 (60,98) |
100 (78,100) |
86 (60,98) |
100 (78,100) |
|
Klebsiella pneumoniae |
40 |
62** (46,77) |
92 (80,98) |
90 (76,97) |
90 (100)# (80,98) |
92 (80,98) |
92 (80,98) |
72 (56,85) |
87 (73,96) |
90 (73,96) |
100 (91,100) |
|
Proteus mirabilis |
10* |
0** (0,31) |
90 (56,99) |
100 (69,100) |
100 (69,100) |
100 (69,100) |
100 (69,100) |
70 (35,93) |
100 (69,100) |
100 (69,100) |
100 (69,100) |
|
Pseudomonas aeruginosa |
34*** |
N/A |
N/A |
87 (72,97) |
94 (80,99) |
N/A |
97 (85,99) |
N/A |
94 (80,99) |
88 (73,97) |
97 (85,99) |
|
Serratia marcescens |
14* |
N/A |
100 (77,100) |
100 (77,100) |
100 (77,100) |
100 (77,100) |
100 (77,100) |
100 (77,100) |
100 (77,100) |
100 (77,100) |
100 (77,100) |
*When fewer than 30 isolates are reported, % susceptible may not reflect robust estimate of population susceptibility
**Reporting of Cefazolin susceptibility for E. coli, Klebsiella spp and Proteus is based on breakpoints for complicated infections - see outpatient E. coli susceptibilities for reporting based on uncomplicated UTI breakpoints
***Pseudomonas aeruginosa isolates do not include isolates from patients with cystic fibrosis.
# Number in parentheses represents the percentage of isolates both fully susceptible and susceptible-dose dependent to cefepime, for each organism. Susceptible-dose dependent isolates of Enterobacteriaceae are those with MIC 4 to 8 micrograms/mL for which a high dose of cefepime (anti-pseudomonal dosing) is anticipated to be active. Consult Pediatric ASP or ID for guidance on treating isolates reported as susceptible-dose dependent.